08:17 AM EDT, 09/25/2025 (MT Newswires) -- Eli Lilly ( LLY ) has stopped its study evaluating the impact of bimagrumab and tirzepatide, alone or in combination, in lowering body weight in obesity patients with type 2 diabetes, an update from the US registry of clinical trials showed Wednesday.

The study was terminated for strategic business reasons, the website showed.

The phase-2 double-blind, randomized, placebo-controlled study, originally intended to last about 13 months, was active for less than a month between May 10 and June 6, according to study details from the website.

A similar study, evaluating bimagrumab and tirzepatide, alone or in combination, in patients without type 2 diabetes, is still active and recruiting participants, the website showed.

Eli Lilly ( LLY ) did not immediately respond to MT Newswires' request for comment.